



Abba Medix Group

Abba Medix Group (CSE:ABA) welcomes Health Canada decision on alternative medical cannabis products and delivery systems

Subsidiary, Blow Vapor, ahead of the curve when it comes to medical marijuana vaporizers.

Toronto, ON, July 10, 2015 - Abba Medix Group Inc. (CSE: ABA), is delighted with Health Canada's prompt response to the recent Supreme Court of Canada decision on alternative medical marijuana products and delivery systems. Ray Rasouli, Abba's President and CEO stated, "This opens the door to non-smoking alternatives for the delivery of medical marijuana's benefits for Canadians. Abba is delighted that Canadians registered to receive medical marijuana will be allowed to choose how to take their medicine including products such as cannabis-infused oils, capsules and vaporizers."

"We have been looking forward to and preparing for Health Canada's direction and the implementation of regulations to create the safe, regulatory environment allowing Canadians and their doctors to decide which medical marijuana delivery system is right for them."

"Abba has been working on the vaporizer technology through our subsidiary Blow Vapor. Our liquid delivery system is ready to go including our dosage metering capacity and we are committed to offering a premium and preferred method of marijuana delivery system in oil form. We will be ready to ship within days after receiving Health Canada's approval on our facility at RedeCan Pharm."

Fernando Di Carlo, CEO of Blow Vapor, an Abba Medix Group company said, "We believe that taking medicinal marijuana using a vaporizer is an attractive, discrete and safe alternative for marijuana delivery."

CEO Ray Rasouli concluded, "Abba anticipated today's Health Canada regulations. We invested in Blow Vapor so we could do the research and product development to meet the needs of Canada's medical marijuana users.

Our investment in vapor technology gives Abba first mover advantage the day Health Canada approves our secure facility."

About Abba Medix Group

Abba Medix Group Inc. (CSE:ABA) is a purveyor of fine Canadian medical marijuana, accessories, events and news. The Company is becoming a marketplace leader through strategic partnerships, mergers, and acquisitions to create a fully-integrated, Canadian medical

marijuana marketplace. Abba's mission is to find and acquire strong marijuana related businesses, product companies, organizational event sponsorships, and research and development opportunities.

Through the pending acquisition of RedeCan, Abba is a licensed medical marijuana grower and sales agent, authorized to supply Canadian patients.

Through Blow Vapor, Abba is providing customers with nothing but the best, most innovative products on the market, offering a wide collection of premium products to fit everyone's lifestyle and vaping preferences.

For more information on the Abba Medix Group, please visit www.abbamedix.com. To shop RedeCan's medical marijuana strains, visit <http://redecanpharm.ca>. To shop for the perfect vape at Blow Vapor, visit www.blowvapor.com.

Cautionary Statements Regarding Forward-Looking Information

Certain statements within this press release relating to the Company constitute "forward-looking statements", within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and / or objectives, sales programs, forecasts and projections, assumptions, expectations, and/or beliefs of future performance, are "forward-looking statements". Such "forward-looking statements" involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including production and / or sales of medical marijuana, quantities of future medical marijuana production, anticipated revenues in connection with such sales, the overall projected size of the market, completion and / or expansion of production facilities, and other information that is based on forecasts of future results, estimates of production not yet determinable, and other key management assumptions. Actual results may differ materially from those expressed or implied by such forward-looking statements and involve risk and uncertainties relating to the Company's historical experience with regulatory changes, timeliness of government approvals for the granting of permits and licenses, changes in medical marijuana prices, actual operating performance of facilities, and other uninsured risks. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

For further information please contact:

Ahmad (Ray) Rasouli
Chief Executive Officer
Abba Medix Group Inc.
Tel: (905) 492-9420